Abstract: Provided are a compound having a cyclohexyl-(alkyl or cycloalkyl-substituted)ethylene-amino-heteroaryl moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound or pharmaceutically acceptable salt thereof not only has excellent inhibitory activity against indoleamine 2,3-dioxygenase (IDO) but also exhibits remarkably high in vivo exposure upon oral administration and therefore the compound or pharmaceutically acceptable salt thereof can be usefully applied for preventing or treating various diseases associated with IDO.
Type:
Application
Filed:
March 22, 2022
Publication date:
May 30, 2024
Applicant:
YUHAN CORPORATION
Inventors:
Gyu-Jin LEE, Eui-Chul LEE, Sol PARK, Dong-Hoon LEE, Su-Hwa KIM, Jong-Suk PARK, Ho-Woong KANG, Hyun-Sik YUN
Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Type:
Grant
Filed:
August 26, 2022
Date of Patent:
May 14, 2024
Assignees:
Yuhan Corporation, Janssen Biotech, Inc.
Inventors:
Byoungmoon Lee, Hyunjoo Lee, Gyu Jin Lee, Su Bin Choi, Sol Park, Heejun Kim, Misong Kim, Young Ae Yoon, Kwan Hoon Hyun, Tae Kyun Kim, Jae Young Sim, Marian C. Bryan, Scott Kuduk, James Campbell Robertson
Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.
Type:
Grant
Filed:
March 17, 2022
Date of Patent:
May 14, 2024
Assignee:
Yuhan Corporation
Inventors:
Sang Ho Oh, Jong Gyun Kim, Se-Woong Oh, Tae Dong Han, Soo Yong Chung, Seong Ran Lee, Kyeong Bae Kim, Young Sung Lee, Woo Seob Shin, Hyun Ju, Jeong Ki Kang, Su Min Park, Dong Kyun Kim
Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Type:
Grant
Filed:
August 26, 2022
Date of Patent:
April 2, 2024
Assignees:
YUHAN CORPORATION, JANSSEN BIOTECH, INC.
Inventors:
Hyunjoo Lee, Su Bin Choi, Young Ae Yoon, Kwan Hoon Hyun, Jae Young Sim, Marian C. Bryan, Scott Kuduk, James Campbell Robertson, Jaekyoo Lee, Paresh Devidas Salgaonkar, Byung-Chul Suh, Jong Sung Koh, So Young Hwang
Abstract: Provided is a method for purifying an anti-4-1BB/anti-HER2 bispecific antibody, the method of which includes carrying out affinity chromatography with a sodium acetate buffer containing a certain inorganic salt as an elution buffer. The purification method of the presently claimed subject matter increases the elution of an antibody in the intact form, thereby being able to provide an anti-4-1BB/anti-HER2 bispecific antibody in the intact form in high purity and high yield.
Type:
Application
Filed:
January 21, 2022
Publication date:
March 14, 2024
Applicant:
YUHAN CORPORATION
Inventors:
Ju-Young PARK, Sung-Hyun CHOI, Yun-Hee CHOI, Won-Tae KIM
Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.
Abstract: The present invention relates to therapies with 3rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC).
Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
Type:
Grant
Filed:
July 6, 2021
Date of Patent:
November 21, 2023
Assignee:
YUHAN CORPORATION
Inventors:
Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Dong Hoon Kim, Su Bin Choi, Sol Park, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
Type:
Grant
Filed:
March 22, 2021
Date of Patent:
October 10, 2023
Assignee:
Yuhan Corporation
Inventors:
Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Su Bin Choi, Sol Park, Dong Hoon Kim, So Young Kim, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha, Eui Chui Lee
Abstract: The present invention provides a pharmaceutical composition comprising (S)—N-(1-(2-((4-amino-3-nitrophenyl)amino)-6-propylpyrimidin-4-yl)pyrrolidin-3-yl)acetamide or a pharmaceutically acceptable salt thereof having an activity as a 5-HT4 receptor agonist and an acidifying agent; and a process for preparing the same.
Type:
Application
Filed:
July 1, 2021
Publication date:
August 17, 2023
Applicant:
YUHAN CORPORATION
Inventors:
Dong-Min Park, Su-Hyeon Kim, Eun-Pa Cheon, Tae-Lin Ha, Jun-Mo Yang, Yoong-Sik Park
Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
Type:
Grant
Filed:
July 6, 2021
Date of Patent:
August 1, 2023
Assignee:
YUHAN CORPORATION
Inventors:
Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.
Type:
Grant
Filed:
March 25, 2022
Date of Patent:
July 25, 2023
Assignee:
Yuhan Corporation
Inventors:
Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.
Type:
Application
Filed:
December 19, 2022
Publication date:
July 6, 2023
Applicant:
YUHAN CORPORATION
Inventors:
Byung Hyun CHOI, In Hwan LIM, Jun Young PARK, Jin Hyoung LEE, Ki Hong KIM, Hae Yong JO, Jun Hwan KIM, Moo Young SONG, Jong Gyun KIM
Abstract: The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said compounds may be usefully applied in the treatment and prevention of FAP-mediated diseases.
Type:
Grant
Filed:
November 5, 2020
Date of Patent:
May 23, 2023
Assignee:
YUHAN CORPORATION
Inventors:
Tae Han Dong, Yoo Hoi Park, Tae Kyun Kim, Jae Eun Joo, Eun Hye Jung, Jae Won Jeong, Hyun Seung Lee, Do Hoon Kim, Ji Eun Yang, Jun Chui Park, Sang Myoun Lim, Na Ry Ha, Da In Chung, Ji Yeong Gal
Abstract: The present invention provides a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist. And also, the present invention provides novel crystalline forms of a hydrochloride of the diaminopyrimidine derivative and processes for preparing the same.
Abstract: Provided are 5-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Type:
Application
Filed:
August 26, 2022
Publication date:
March 23, 2023
Applicants:
YUHAN CORPORATION, JANSSEN BIOTECH, INC.
Inventors:
Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
Abstract: Provided are 6-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Type:
Application
Filed:
August 26, 2022
Publication date:
March 23, 2023
Applicants:
YUHAN CORPORATION, JANSSEN BIOTECH, INC.
Inventors:
Hyunjoo LEE, Su Bin CHOI, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM
Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Type:
Application
Filed:
August 26, 2022
Publication date:
March 23, 2023
Applicants:
YUHAN CORPORATION, JANSSEN BIOTECH, INC.
Inventors:
Hyunjoo LEE, Su Bin CHOI, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell Robertson, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Type:
Application
Filed:
August 26, 2022
Publication date:
March 23, 2023
Applicants:
YUHAN CORPORATION, JANSSEN BIOTECH, INC.
Inventors:
Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Sol PARK, Heejun KIM, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Tae Kyun KIM, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON
Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.
Type:
Grant
Filed:
April 20, 2018
Date of Patent:
January 24, 2023
Assignee:
YUHAN CORPORATION
Inventors:
Byung Hyun Choi, In Hwan Lim, Jun Young Park, Jin Hyoung Lee, Ki Hong Kim, Hae Yong Jo, Jun Hwan Kim, Moo Young Song, Jong Gyun Kim